Hira S Mian1, Mark A Fiala2, Tanya M Wildes3. 1. Juravinski Cancer Center, Department of Oncology, McMaster University, Hamilton, Ontario, Canada. 2. Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO. 3. Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO. Electronic address: twildes@wustl.edu.
Abstract
BACKGROUND: Multiple myeloma is an incurable hematologic malignancy with significant recent treatment advances; however, the magnitude of treatment burden among patients in the first year after diagnosis has yet to be fully researched and reported. PATIENTS AND METHODS: Patients with multiple myeloma newly diagnosed between 2007 and 2013 were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases. Treatment burden was captured as the number of total days with a health care encounter (including acute care and outpatient visits), oncology and nononcology physician visits, and the number of new prescriptions within the first year after diagnosis. Logistic regression was used to identify factors associated with high treatment burden. RESULTS: A total of 3065 patients were included in the analysis. There was a substantial burden of treatment within the first year after diagnosis (median, 77 days; interquartile range, 55-105 days), which was highest during the first 3 months. Patients with high comorbidities (adjusted odds ratio [aOR] 1.27 per 1-point increase in Charlson comorbidity index, P < .001), poor performance status (aOR 1.85, P < .001), myeloma-related end organ damage, particularly bone disease (aOR 2.28, P < .001), and those who underwent autologous stem-cell transplantation (aOR 2.41, P < .001) were more likely to have a higher treatment burden. CONCLUSION: There is considerable burden of treatment in patients with newly diagnosed multiple myeloma within the first year after diagnosis, particularly within the first 3 months. Future tailored interventions aimed at optimizing this treatment burden when possible while simultaneously providing support to manage it may improve patient-centered care.
BACKGROUND: Multiple myeloma is an incurable hematologic malignancy with significant recent treatment advances; however, the magnitude of treatment burden among patients in the first year after diagnosis has yet to be fully researched and reported. PATIENTS AND METHODS: Patients with multiple myeloma newly diagnosed between 2007 and 2013 were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases. Treatment burden was captured as the number of total days with a health care encounter (including acute care and outpatient visits), oncology and nononcology physician visits, and the number of new prescriptions within the first year after diagnosis. Logistic regression was used to identify factors associated with high treatment burden. RESULTS: A total of 3065 patients were included in the analysis. There was a substantial burden of treatment within the first year after diagnosis (median, 77 days; interquartile range, 55-105 days), which was highest during the first 3 months. Patients with high comorbidities (adjusted odds ratio [aOR] 1.27 per 1-point increase in Charlson comorbidity index, P < .001), poor performance status (aOR 1.85, P < .001), myeloma-related end organ damage, particularly bone disease (aOR 2.28, P < .001), and those who underwent autologous stem-cell transplantation (aOR 2.41, P < .001) were more likely to have a higher treatment burden. CONCLUSION: There is considerable burden of treatment in patients with newly diagnosed multiple myeloma within the first year after diagnosis, particularly within the first 3 months. Future tailored interventions aimed at optimizing this treatment burden when possible while simultaneously providing support to manage it may improve patient-centered care.
Authors: Antonio Palumbo; Sara Bringhen; Maria-Victoria Mateos; Alessandra Larocca; Thierry Facon; Shaji K Kumar; Massimo Offidani; Philip McCarthy; Andrea Evangelista; Sagar Lonial; Sonja Zweegman; Pellegrino Musto; Evangelos Terpos; Andrew Belch; Roman Hajek; Heinz Ludwig; A Keith Stewart; Philippe Moreau; Kenneth Anderson; Hermann Einsele; Brian G M Durie; Meletios A Dimopoulos; Ola Landgren; Jesus F San Miguel; Paul Richardson; Pieter Sonneveld; S Vincent Rajkumar Journal: Blood Date: 2015-01-27 Impact factor: 22.113
Authors: Viet-Thi Tran; Victor M Montori; David T Eton; Dan Baruch; Bruno Falissard; Philippe Ravaud Journal: BMC Med Date: 2012-07-04 Impact factor: 8.775
Authors: Meryl Brod; Mette Hammer; Torsten Christensen; Suzanne Lessard; Donald M Bushnell Journal: Health Qual Life Outcomes Date: 2009-09-09 Impact factor: 3.186
Authors: David T Eton; Djenane Ramalho de Oliveira; Jason S Egginton; Jennifer L Ridgeway; Laura Odell; Carl R May; Victor M Montori Journal: Patient Relat Outcome Meas Date: 2012-08-24
Authors: Carl R May; David T Eton; Kasey Boehmer; Katie Gallacher; Katherine Hunt; Sara MacDonald; Frances S Mair; Christine M May; Victor M Montori; Alison Richardson; Anne E Rogers; Nathan Shippee Journal: BMC Health Serv Res Date: 2014-06-26 Impact factor: 2.655
Authors: Daniel Auclair; Carol Mansfield; Mark A Fiala; Ajai Chari; Craig E Cole; Jonathan L Kaufman; Gregory J Orloff; David S Siegel; Jeffrey A Zonder; Brennan Mange; Jennifer Yesil; Mehul Dalal; Joseph R Mikhael Journal: Patient Prefer Adherence Date: 2022-03-01 Impact factor: 2.711